-
197
-
168
-
97
-
96
-
91
Guidelines
CUA guidelines are divided into two categories:
- Guidelines will be created for content areas that are important to urologists where there is high-level (e.g., RCTs) evidence to support recommendations. Note that although moving forward the CUA will be employing GRADE methodology for all its major guidelines, until we shift exclusively to this model, guidelines will be updated using the methodology in which they were originally created.
- Expert Reports are for topics somewhat peripheral to a urologist’s practice or when most recommendations need to be formed by experts on consensus. Prior to 2025, CUA Expert Reports may have been entitled Best Practice Reports or Consensus Statements.
Reproduction of any part of the published CUA guideline portfolio requires the express written consent of the Canadian Urological Association (CUA).
*Please note, the CUA is currently reviewing its guideline portfolio and will be updating/recategorizing topics as appropriate. For any questions, don't hesitate to contact the CUA Guidelines Manager at adriana.modica@cua.org.*
CUA GUIDELINES
- UPDATE 2025 - CUA-CUOG: Metastatic castration-resistant prostate cancer, August 2025
- UPDATE 2025 - CUA-CUOG: Metastatic castration-naive and castration-sensitive prostate cancer, May 2025
- Interstitial cystitis/bladder pain syndrome, April 2025
- Muscle-invasive bladder cancer, January 2025
- Female stress urinary incontinence, April 2024
- Genetic testing in prostate cancer, October 2023
- Pediatric patients with neurogenic lower urinary tract dysfunction (full-text version), October 2023
- Workup and management of azoospermia, August 2023
- Management of cystic renal lesions, June 2023
- Diagnosis, management, and followup of the incidentally discovered adrenal mass, February 2023
- UPDATE 2022 - CUA/CUOG: Castration-resistant prostate cancer, November 2022
- UPDATE 2022 - Male lower urinary tract symptoms/benign prostatic hyperplasia, August 2022
- UPDATE 2022 - ADT: Adverse events and management strategies, August 2022
- Testicular germ cell cancer, June 2022
- Evaluation and medical management of kidney stones, June 2022
- UPDATE 2022 - Prostate cancer screening and early diagnosis: Endorsement of 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging, April 2022
- Small renal masses - Full-text, February 2022
- Small renal masses - Summary of recommendations, February 2022
- Ureteral calculi - Abridged version, December 2021
- Erectile dysfunction, October 2021
- Non-muscle-invasive bladder cancer, August 2021
- Muscle-invasive bladder cancer, August 2019
- Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Executive summary, June 2019
- Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text, June 2019
- AUA/CUA/SUFU: Recurrent uncomplicated urinary tract infections in women, May 2019
- Perioperative thromboprophylaxis and management of anticoagulation, April 2019
- Followup of patients after treatment of non-metastatic renal cell carcinoma, August 2018
- Peyronie's disease and congenital penile curvature, May 2018
- CUA/PUC: Investigation and management of antenatally detected hydronephrosis, April 2018
- CUA/PUC: Diagnosis, management, and followup of cryptorchidism, July 2017
- Adult overactive bladder: Full text, May 2017
- Adult overactive bladder: Executive summary, May 2017
- Diagnosis and treatment of interstitial cystitis/bladder pain syndrome, May 2016 (Update pending)
- Multicystic dysplastic kidney (MCDK) in the neonate: The role of the urologist, February 2016
- Postoperative surveillance of upper urinary tract urothelial carcinoma, October 2013 (Update pending)
- Genetic screening for hereditary renal cell cancers, October 2013
- Prostatitis, October 2011 (Update pending)
CUA EXPERT REPORTS
- Management of unresectable locally advanced and metastatic urothelial carcinoma, December 2024
- KCRNC: Management of non-clear cell renal cell carcinoma, October 2024
- KCRNC: Adjuvant therapy for renal cell carcinoma, May 2023
- Nocturia, July 2022
- UPDATE 2022 - Vasectomy, May 2022
- Bone health in prostate cancer, December 2021
- PSMA/PET CT and PET/MRI in prostate cancer, June 2021
- KCRNC: Management of advanced kidney cancer 2021 update, April 2021
- Holmium: YAG laser eye safety, December 2020
- Diagnosis and management of sporadic angiomyolipomas, November 2020
- Catheter use, July 2020
- CUA/GUMOC: Management of urachal cancer, March 2020
- KCRNC: The role of renal mass biopsy in the management of kidney cancer, December 2019
- Long-term surveillance following resection of pheochromocytoma, December 2019
- Sports and the solitary kidney — What primary caregivers of a young child with a single kidney should know (2019 update), October 2019
- KCRNC: The role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma, June 2019
- Diagnosis and management of radiation-induced hemorrhagic cystitis, February 2019
- Chronic scrotal pain, June 2018
- CAGMO: Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC), October 2013
- CAGMO: Management of small cell carcinoma of the bladder, February 2013
- 2012 update: Adult Urinary Incontinence Collaborative Consensus, October 2012
CUA-ENDORSED GUIDELINES
- ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group: Kidney involvement in tuberous sclerosis complex, August 2024
- CCO: Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer, February 2022
- NSWOCC/UNC: Urinary diversions position statement, January 2022
- Multiparametric magnetic resonance imaging for pre-treatment local staging of prostate cancer: A Cancer Care Ontario clinical practice guideline, October 2016
- Active surveillance for the management of localized prostate cancer: Guideline recommendations, June 2015






